Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal

Samsung Biologics is acceptable to get PolyPeptide Group done an all-cash nationalist tender connection valued astatine SFr1.46bn ($1.81bn).

The projected connection is acceptable astatine SFr44.31 per stock for 100% of PolyPeptide's afloat diluted stock capital, excluding treasury shares.

Completion of the woody is anticipated towards the extremity of this year, contingent connected gathering a minimum acceptance threshold of astir 67%, arsenic good arsenic obtaining required regulatory approvals and satisfying different conditions nether Swiss takeover law.

Acting done its autarkic and non-conflicted members, PolyPeptide's committee unanimously recommends that shareholders judge the tender offer, taxable to the presumption outlined successful the forthcoming prospectus.

The company's largest shareholder, with astir 55.65% of outstanding shares (excluding treasury shares), has provided an irrevocable undertaking to tender its shares into the offer.

By moving guardant with this offer, Samsung Biologics intends to grow its presumption beyond antibodies and antibody-drug conjugates (ADCs), targeting the increasing request for peptide-based therapeutics.

PolyPeptide operates facilities successful Belgium, France, India, Sweden, and the US, arsenic good arsenic a firm bureau successful Switzerland and an Innovation Centre successful France.

The institution specialises successful peptide-based progressive pharmaceutical ingredients and has produced much than 1,000 therapeutic peptides successful its history.

Samsung Biologics CEO and committee of directors president John Rim said: "This acquisition reinforces our semipermanent maturation strategy by not lone broadening our work portfolio with modality enlargement into peptides including GLP-1, but by besides boosting our geographic scope and proximity further wrong the US, Europe, and India.

"We highly worth PolyPeptide's world-class employees, industry-leading capabilities, and planetary operational footprint, and look guardant to leveraging the complementary strengths of PolyPeptide and Samsung Biologics successful our continued maturation supporting clients arsenic the CDMO of prime for decades to come."

The connection terms reflects a 40% premium to PolyPeptide's past undisturbed stock terms arsenic of 10 April 2026, and astir a 11.6% premium to the 60-day volume-weighted mean price.

If completed, Samsung Biologics plans to get each remaining shares and delist PolyPeptide from the SIX Swiss Exchange. JP Morgan is serving arsenic exclusive fiscal advisor to Samsung Biologics.

Ernst & Young Han Young is serving arsenic accounting and taxation advisor portion O'Melveny & Myers and Schellenberg Wittmer are providing ineligible advice.